BioStock: Cereno Scientific’s CS014 attracts interest from medical community
Cereno Scientific’s portfolio of programmes continue to attract attention in the medical community, this time with preclinical drug candidate CS014, an epigenetic modulator based on HDAC inhibition. Earlier this month, the company nominated CS014 as candidate drug from the preclinical HDACi programme to develop and bring into the clinic. Cereno has now been awarded acceptance of an abstract with promising data showing CS014’s ability to prevent thrombosis without increased risk of bleeding. The abstract will be presented at the ESC Congress 2022.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/